Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 19 of 1,261
  1. US 12391760

    Method of treating primary sclerosing cholangitis

    Takeda Pharmaceutical Company Limited Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  2. US 12391642

    Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors

    NIKANG THERAPEUTICS, INC. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  3. US 12391658

    Sulfoxide and sulfone glucokinase activators and methods of use thereof

    VTV THERAPEUTICS LLC Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  4. US 12391732

    Articles comprising a silk polypeptide for antigen delivery

    Ludwig-Maximilians-Universitat Munchen Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  5. US 12391739

    Method for producing gamma delta T cells

    Takeda Pharmaceutical Company Limited Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  6. US 12389889

    Mouse having a humanized cluster of differentiation 47 gene

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  7. US 12391765

    Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies

    Takeda Pharmaceutical Company Limited Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  8. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  9. US 12390462

    Muscarinic acetylcholine M1 receptor antagonists

    Contineum Therapeutics, Inc. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  10. US 12390463

    Dosage forms and regimens for amino acid compounds

    Pliant Therapeutics, Inc. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  11. US 12390427

    Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  12. US 12389931

    Oyster peptide with effect of improving sexual function and preparation method thereof

    CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES CO., LTD. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  13. US 12391686

    Compounds and uses thereof

    FOGHORN THERAPEUTICS INC. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  14. US 12390497

    Microbial strains for virus inhibition

    MICROBIAL DISCOVERY GROUP, LLC Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  15. US 12391741

    T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof

    MiNK Therapeutics, Inc. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  16. US 12391750

    Anti-C1S antibodies and methods of use thereof

    Bioverativ USA Inc. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  17. US 12391742

    Anti-KRAS-G12D T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  18. US 12390483

    Compounds and methods for treating neurological and cardiovascular conditions

    The Board of Regents of the University of Texas System Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  19. US 12390496

    Methods for treating ulcerative colitis

    Finch Therapeutics Holdings LLC Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  20. US 12391643

    Substituted amino-thiol and amino-disulfide compounds, and uses thereof

    The Regents of the University of California Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  21. US 12391753

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  22. US 12391923

    SIRPΞ±-silenced natural killer (NK) cells

    The Regents of the University of California Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  23. US 12390512

    Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae

    SHANGHAI REINOVAX BIOLOGICS CO., LTD Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted
  24. US 12391669

    Substituted pyrimidines as IRE1 kinase inhibitors

    The Regents of the University of California et al. Β· Granted Aug 19, 2025 Β· Expires Aug 14, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.